Remdesivir for Patients Hospitalized with COVID-19: Evidence of Effectiveness from Cohort Studies in the Omicron Era

IF 8.2 1区 医学 Q1 IMMUNOLOGY Clinical Infectious Diseases Pub Date : 2024-10-24 DOI:10.1093/cid/ciae515
Daniel R Kuritzkes
{"title":"Remdesivir for Patients Hospitalized with COVID-19: Evidence of Effectiveness from Cohort Studies in the Omicron Era","authors":"Daniel R Kuritzkes","doi":"10.1093/cid/ciae515","DOIUrl":null,"url":null,"abstract":"Remdesivir is the only antiviral approved for treatment of persons hospitalized for COVID-19. This supplement presents new information from real-world cohort studies reporting reduced mortality in at-risk populations and reductions in re-admission for COVID-19 in the Omicron era.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"90 1","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae515","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Remdesivir is the only antiviral approved for treatment of persons hospitalized for COVID-19. This supplement presents new information from real-world cohort studies reporting reduced mortality in at-risk populations and reductions in re-admission for COVID-19 in the Omicron era.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
雷米替韦治疗 COVID-19 住院患者:欧米茄时代队列研究的有效性证据
雷米替韦是唯一获准用于治疗 COVID-19 住院患者的抗病毒药物。本增刊介绍了来自真实世界队列研究的新信息,这些研究报告显示,在 Omicron 时代,高危人群的死亡率降低了,COVID-19 的再入院率也降低了。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Infectious Diseases
Clinical Infectious Diseases 医学-传染病学
CiteScore
25.00
自引率
2.50%
发文量
900
审稿时长
3 months
期刊介绍: Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.
期刊最新文献
HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics. Predictors of persistent fever among patients with suspected infective endocarditis: think outside the box. Rewriting the Script. Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial. Choosing Wisely: Effectiveness and Safety of Antibiotic Prophylaxis in Close Contacts of Invasive Group A Streptococci Infection.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1